Landos Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	37.55	36.64	8.31	2.42	9.81	0.36
Short-Term Investments	0	7.76	82.58	25.72	40.16	0
Cash & Cash Equivalents	37.55	44.4	90.88	28.13	49.97	0.36
Cash Growth	-15.43%	-51.14%	223.03%	-43.69%	13817.83%	-
Other Current Assets	0.49	0.85	1.27	1.75	0.15	2.13
Total Current Assets	38.04	45.25	92.15	29.89	50.11	2.49
Property, Plant & Equipment	0	0	0.71	0.44	0.36	0.3
Other Long-Term Assets	0	0	0.03	0	0.01	0
Total Long-Term Assets	0	0	0.73	0.44	0.37	0.3
Total Assets	38.04	45.25	92.88	30.33	50.48	2.8
Accounts Payable	1.38	3.44	12.91	8.61	2.05	1.69
Other Current Liabilities	4.87	2.69	3.7	2.43	0.98	0.1
Total Current Liabilities	6.25	6.12	16.61	11.03	3.03	1.8
Other Long-Term Liabilities	0	0	0	0.28	0	0
Total Long-Term Liabilities	0	0	0	0.28	0	0
Total Liabilities	6.25	6.12	16.61	11.31	3.03	1.8
Retained Earnings	-155.36	-133.43	-94.15	-55.73	-25.59	-9.14
Comprehensive Income	0	-0.06	-0.23	0.01	-0.08	0
Shareholders' Equity	31.79	39.13	76.27	-54.02	-25.58	1
Net Cash / Debt	37.55	44.4	90.88	28.13	49.97	0.36
Net Cash / Debt Growth	-15.43%	-51.14%	223.03%	-43.69%	13817.83%	-
Net Cash Per Share	5.98	11.03	24.20	23.01	43.85	0.35
Working Capital	31.79	39.13	75.54	18.85	47.08	0.7
Book Value Per Share	5.07	9.72	20.31	-44.17	-22.45	0.97

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).